Epidemiology, Pathogenesis, and Risk Factors

  • Gauri Mankekar


Invasive fungal sinusitis has been reported from all over the world, but its incidence varies widely with higher frequency reported in Sudan [1], southwestern states of the USA, and India, which have a hot and dry climate. The incidence seems to be higher in India than elsewhere in the world [2]. The true incidence of mucormycosis is unknown and probably underestimated due to the difficulties in antemortem diagnosis and the low autopsy rates in patients who die in the setting of either leukemia or stem cell transplant [3]. However, there is a consensus that there has been an overall increase in the incidence of all types of fungal sinusitis [2, 4]. At M.D. Anderson Cancer Center, Texas, the number of reported cases increased from 8 per 100,000 admissions during 1989–1993 to 17 per 100,000 admissions during 1994–1998 [4].


Iron Overload Aplastic Anemia Fungal Spore Invasive Fungal Infection Hematological Condition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Veress B, Malik OA, Tayeb AA, El Daoud S, El Mahgoub S, El Hassan AM. Further observations on the primary paranasal Aspergillus granuloma in Sudan. Am J Trop Med Hyg. 1973;22:765–72.PubMedGoogle Scholar
  2. 2.
    Chakrabarti A, Sharma SC. Paranasal sinus mycoses. Indian J Chest Dis Allied Sci. 2000;42:293–304.PubMedGoogle Scholar
  3. 3.
    Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15 year period (1989–2003). Haematologica. 2006;91(7):986–9.PubMedGoogle Scholar
  4. 4.
    Kontoyiannis DP, Wessel VC, Bodey GP, Rolston VI. Zygomycosis in the 1990s in a tertiary care cancer center. Clin Infect Dis. 2000;30:851–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Talmi YP, Goldschmeid-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127:22–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med. 1996;35:540–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Chakrabarti A, Sharma SC, Chander J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg. 1992;107:745–50.PubMedGoogle Scholar
  8. 8.
    Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31–47.PubMedCrossRefGoogle Scholar
  9. 9.
    Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460–6.PubMedGoogle Scholar
  10. 10.
    Mileshkin L, Slavin M, Seymour JF, McKenzie A. Successful treatment of rhinocerebral zygomycosis using liposomal nystatin. Leuk Lymphoma. 2001;42:1119–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Wueppenhorst N, Lee M-K, Rappold E, Kayser G, Beckervordersandforth J, de With K, Serr A. Rhino-orbitocerebral zygomycosis caused by Conidiobolus incongruous in an immunocompromised patient in Germany. J Clin Microbiol. 2010;48(11):4322–5. doi:  10.1128/JCM.01188-10. Epub 2010 Sep 22.Google Scholar
  12. 12.
    Hejny C, Kerrison JB, Newman NJ, Stone CM. Rhino-orbital mucormycosis in a patient with acquired immunodeficiency syndrome (AIDS) and neutropenia. Am J Ophthalmol. 2001;132:111–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Lehrer RI, Howard DH, et al. Mucormycosis. Ann Intern Med. 1980;9:93–108.CrossRefGoogle Scholar
  14. 14.
    Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogenic bone transplant recipients. Clin Infect Dis. 2001;32:1319–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high risk hematologic malignancies and recipients of allogenic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Morduchowicz G, Shmueli D, Shapira Z, et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of literature. Rev Infect Dis. 1986;8:441–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Jimenez C, Lumbreras C, Paseiro G, et al. Treatment of mucor infection after liver or pancreas-kidney transplantation. Transplant Proc. 2002;34:82–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Trifilio SM, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425.PubMedCrossRefGoogle Scholar
  19. 19.
    Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis. Report of four cases and review. Rev Infect Dis. 1989;11:741–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Espinel-Ingroff A, Oakley LA, Kerkering TM. Opportunistic zygomycotic infections. Mycopathologica. 1987;97:33–41.CrossRefGoogle Scholar
  21. 21.
    Boelaert JR, Fenves AZ, Coburn JW. Mucormycosis among patients on dialysis. N Engl J Med. 1989;321:190–1.PubMedGoogle Scholar
  22. 22.
    Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med. 1989;87:468–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012;97(10):1459–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and mycobacterium tuberculosis infection. J Clin Virol. 2001;20(3):123–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Schaible UE, Kauffman SH. Iron and microbial infection. Nat Rev Microbiol. 2004;2(12):946–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Boelaert JR, Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–86.PubMedCrossRefGoogle Scholar
  27. 27.
    Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and deferoxamine on Rhizopus infection. Mycopathologica. 1990;110:87–90.CrossRefGoogle Scholar
  28. 28.
    Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55(3):251–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Boelaert JR Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host’s iron status on tuberculosis. J Infect Dis. 2007;195(12):1745–53.CrossRefGoogle Scholar
  30. 30.
    Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Mycopathologica. 1990;110:87–90.CrossRefGoogle Scholar
  31. 31.
    Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Garcia-Covarrubias L, Bartlett R, Bartlett DM, Wasserman RJ. Rhino-orbito-cerebral mucormycosis attributed to Apophysomyces elegans in an immunocompetent individual: a case report and review of literature. J Trauma. 2001;50:353–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997–2020.PubMedCrossRefGoogle Scholar
  34. 34.
    Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect. 2009;15(50):93–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus active anti fungal therapy: a case controlled observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev. 2005;18(3):556–69.PubMedCrossRefGoogle Scholar
  38. 38.
    Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.PubMedCrossRefGoogle Scholar
  39. 39.
    Kontoyiannis DP, Lewis RE. Invasive zygomycosis: an update on pathogenesis, clinical manifestations and management. Infect Dis Clin North Am. 2006;20(3):581–607.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.ENTPD Hinduja HospitalMahim, MumbaiIndia

Personalised recommendations